Taro-Testosterone Gel

Taro-Testosterone Gel is a topical testosterone product used to treat men with low testosterone levels (hypogonadism). It may also be prescribed off-label as part of gender-affirming hormone therapy for transgender men and some nonbinary individuals, as well as in select cases for women. As a gel, it delivers testosterone through the skin into the bloodstream.

In Canada, Taro-Testosterone Gel is a generic topical testosterone product manufactured by Taro Pharmaceuticals. It is available in two strengths, each identified by a unique Drug Identification Number (DIN):

• 2.5 g unit-dose gel packets – DIN: 02463792
• 5 g unit-dose gel packets – DIN: 02463806

Each packet contains a fixed amount of testosterone. At a 1% concentration, a 2.5 g packet provides 25 mg, while a 5 g packet provides 50 mg. Smaller packets can be used for dose adjustments, while 5 g packets are commonly used for standard daily dosing. Multiple packets may be used if higher doses are prescribed.

Like other topical testosterone products, it is applied once daily and is designed to maintain stable hormone levels with consistent use. Differences in formulation and carrier ingredients may affect absorption and tolerability for some patients.

Because it is often used as a lower-cost alternative to brand-name gels, Taro-Testosterone Gel can be an important option during shortages. If supply is limited, patients may need to switch to other gels (such as AndroGel or Testim) or to a different type of testosterone, such as injections. Monitoring is usually needed when switching between products.

Because multiple gel products are available in Canada, shortages are often easier to manage by switching within this category, although differences in format and dosing still matter.

Public Coverage

Taro-Testosterone Gel may be covered by provincial and territorial public drug plans in Canada. Generic products like this are often considered before brand-name options such as AndroGel or Testim. Coverage usually requires approval and depends on medical criteria set by each plan.